Impact of Molecular Biology in Diagnosis, Prognosis, and Therapeutic Management of BCR::ABL1-Negative Myeloproliferative Neoplasm - Archive ouverte HAL Access content directly
Journal Articles Cells Year : 2023

Impact of Molecular Biology in Diagnosis, Prognosis, and Therapeutic Management of BCR::ABL1-Negative Myeloproliferative Neoplasm

(1, 2) , (3) , (1, 2) , (4) , (2, 5) , (6) , (3) , (3) , (3) , (2, 3) , (7, 8) , (2, 9) , (2, 3, 10) , (2, 3, 10)
1
2
3
4
5
6
7
8
9
10

Abstract

BCR::ABL1-negative myeloproliferative neoplasms (MPNs) include three major subgroups—polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF)—which are characterized by aberrant hematopoietic proliferation with an increased risk of leukemic transformation. Besides the driver mutations, which are JAK2, CALR, and MPL, more than twenty additional mutations have been identified through the use of next-generation sequencing (NGS), which can be involved with pathways that regulate epigenetic modifications, RNA splicing, or DNA repair. The aim of this short review is to highlight the impact of molecular biology on the diagnosis, prognosis, and therapeutic management of patients with PV, ET, and PMF.
Fichier principal
Vignette du fichier
cells-12-00105.pdf (934.59 Ko) Télécharger le fichier
Origin : Publisher files allowed on an open archive

Dates and versions

hal-03935016 , version 1 (11-01-2023)

Licence

Attribution - CC BY 4.0

Identifiers

Cite

Norman Abbou, Pauline Piazzola, Jean Gabert, Vincent Ernest, Robin Arcani, et al.. Impact of Molecular Biology in Diagnosis, Prognosis, and Therapeutic Management of BCR::ABL1-Negative Myeloproliferative Neoplasm. Cells, 2023, 12 (1), pp.105. ⟨10.3390/cells12010105⟩. ⟨hal-03935016⟩
0 View
0 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More